Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kura Oncology Inc KURA

Healthcare Biotechnology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that... see more

Recent & Breaking News (NDAQ:KURA)

Kura Oncology Reports Second Quarter 2020 Financial Results

GlobeNewswire August 6, 2020

Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 4, 2020

Kura Oncology to Report Second Quarter 2020 Financial Results

GlobeNewswire July 30, 2020

Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum

GlobeNewswire June 11, 2020

Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma

GlobeNewswire May 29, 2020

Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

GlobeNewswire May 13, 2020

Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

GlobeNewswire May 8, 2020

Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020

GlobeNewswire May 7, 2020

Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock

GlobeNewswire May 6, 2020

Kura Oncology Announces Commencement of Public Offering of Common Stock

GlobeNewswire May 5, 2020

Kura Oncology Reports First Quarter 2020 Financial Results

GlobeNewswire May 4, 2020

Kura Oncology to Report First Quarter 2020 Financial Results

GlobeNewswire April 29, 2020

Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

GlobeNewswire March 3, 2020

Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 25, 2020

Kura Oncology to Participate in Three Upcoming Investor Conferences

GlobeNewswire February 19, 2020

Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 18, 2020

Kura Oncology Announces Transition of Chief Medical Officer

GlobeNewswire January 23, 2020

Kura Oncology to Present at J.P. Morgan Healthcare Conference

GlobeNewswire January 9, 2020

Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

GlobeNewswire January 6, 2020

Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial

GlobeNewswire December 16, 2019